Federal Trade Commission vote on Aug. 31 consent agreement allowing Roche to acquire 60% of Genentech was 3-2, with Commissioners Terry Calvani and Deborah Owen dissenting. Calvani said he would have voted yes if agreement, as recommended by FTC staff, "also provided relief" from potential anticompetitive effect of "gamma interferon and recombinant DNA products under development by Roche." Agreement calls for Genentech to divest interest in vitamin C and Roche to license CD4 in the U.S. and divest human growth hormone-promoting factor ("The Pink Sheet" Sept. 3, T&G-1). Consent agreement appeared in Sept. 17 Federal Register for 60-day comment period.
You may also be interested in...
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.